Literature DB >> 1358764

Use of cimetidine and other peptic ulcer drugs in Denmark 1977-1990 with analysis of the risk of gastric cancer among cimetidine users.

H Møller1, A Nissen, J Mosbech.   

Abstract

The prevalence of use of peptic ulcer drugs in the Danish population is described at two points in time using registrations of applications for reimbursement. In 1977-81, the prevalence of use of cimetidine was 0.4% in men and 0.2% in women. In 1989-90, the prevalence of use of peptic ulcer drugs was 1.3% in men and 1.2% in women. The increase in prevalence was apparent in all age groups, but most pronounced at relatively old age. The median age of users increased from 55 years in 1977-81 to 63 years in 1989-90. The data indicated that a third of those who used peptic ulcer drugs in 1977-81 also used these drugs in 1989-90, conditional on surviving this period. The probability of becoming a long term user was highest for those who were 50-69 years in 1977-81. The incidence of gastric cancer was investigated in the cohort of persons who used cimetidine in 1977-81. An excess risk of gastric cancer was apparent in the first years after start of cimetidine use. This is thought to reflect a selection bias. Significantly increased incidence was also observed in women seven years or longer after start of cimetidine use (RR = 4.7; 95% CI: 1.7-10.3). This estimate was, however, based on only six cases, and a similar pattern was not observed in men.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1358764      PMCID: PMC1379479          DOI: 10.1136/gut.33.9.1166

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  20 in total

1.  [Basis for ulcus therapy in general practice].

Authors:  M Gormsen; K S Jensen; P Matzen; O Bonnevie
Journal:  Ugeskr Laeger       Date:  1988-09-12

2.  Late mortality after vagotomy and drainage for duodenal ulcer.

Authors:  P C Watt; C C Patterson; T L Kennedy
Journal:  Br Med J (Clin Res Ed)       Date:  1984-05-05

3.  Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole.

Authors:  B K Sharma; I A Santana; E C Wood; R P Walt; M Pereira; P Noone; P L Smith; C L Walters; R E Pounder
Journal:  Br Med J (Clin Res Ed)       Date:  1984-09-22

4.  Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia.

Authors:  O Nyrén; H O Adami; S Bates; R Bergström; S Gustavsson; L Lööf; A Nyberg
Journal:  N Engl J Med       Date:  1986-02-06       Impact factor: 91.245

5.  Intragastric nitrites, nitrosamines, and bacterial overgrowth during cimetidine treatment.

Authors:  R W Stockbrugger; P B Cotton; N Eugenides; B A Bartholomew; M J Hill; C L Walters
Journal:  Gut       Date:  1982-12       Impact factor: 23.059

6.  Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data.

Authors:  P Sipponen; M Kekki; J Haapakoski; T Ihamäki; M Siurala
Journal:  Int J Cancer       Date:  1985-02-15       Impact factor: 7.396

7.  Cimetidine and gastric cancer: preliminary report from post-marketing surveillance study.

Authors:  D G Colin-Jones; M J Langman; D H Lawson; M P Vessey
Journal:  Br Med J (Clin Res Ed)       Date:  1982-11-06

8.  Histamine-2-receptor antagonists and gastric cancer risk.

Authors:  C La Vecchia; E Negri; B D'Avanzo; S Franceschi
Journal:  Lancet       Date:  1990-08-11       Impact factor: 79.321

9.  Long term management of duodenal ulcer in general practice: how best to use cimetidine?

Authors:  A G Wade; D Rowley-Jones
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-02

10.  Cancer risk following pernicious anaemia.

Authors:  L A Brinton; G Gridley; Z Hrubec; R Hoover; J F Fraumeni
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

View more
  11 in total

1.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

Review 2.  Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies.

Authors:  Jeong Soo Ahn; Chun-Sick Eom; Christie Y Jeon; Sang Min Park
Journal:  World J Gastroenterol       Date:  2013-04-28       Impact factor: 5.742

Review 3.  Switching drug availability from prescription only to over-the-counter status. Are elderly patients at increased risk?

Authors:  S I Benrimoj; J H Langford; M G Bowden; E J Triggs
Journal:  Drugs Aging       Date:  1995-10       Impact factor: 3.923

4.  Safety implications of the over-the-counter availability of H2-antagonists.

Authors:  M Andersen; J S Schou
Journal:  Drug Saf       Date:  1993-03       Impact factor: 5.606

5.  Gastric cancer risk after vagotomy.

Authors:  G Lundegårdh; A Ekbom; J K McLaughlin; O Nyrén
Journal:  Gut       Date:  1994-07       Impact factor: 23.059

Review 6.  Why is the coexistence of gastric cancer and duodenal ulcer rare? Examination of factors related to both gastric cancer and duodenal ulcer.

Authors:  Hideyuki Ubukata; Hiroyuki Nagata; Takanobu Tabuchi; Satoru Konishi; Teruhiko Kasuga; Takafumi Tabuchi
Journal:  Gastric Cancer       Date:  2011-01-20       Impact factor: 7.370

Review 7.  Nerves in gastrointestinal cancer: from mechanism to modulations.

Authors:  Nathalie Vaes; Musa Idris; Werend Boesmans; Maria M Alves; Veerle Melotte
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-09-02       Impact factor: 73.082

Review 8.  A comparative overview of the adverse effects of antiulcer drugs.

Authors:  D W Piper
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

9.  Effect of gastric secretion on penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into gastric mucosa of rats.

Authors:  K K Ovrebø; H Sørbye; S Kvinnsland; K Grong; K Svanes
Journal:  Dig Dis Sci       Date:  1998-09       Impact factor: 3.199

10.  Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.

Authors:  Nele Brusselaers; Karl Wahlin; Lars Engstrand; Jesper Lagergren
Journal:  BMJ Open       Date:  2017-10-30       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.